Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 20

1L NSCLC: Keynote 021
Langer CJ, et al. Lancet Oncol 2016
1...,10,11,12,13,14,15,16,17,18,19 21,22,23,24,25,26,27,28,29,30,...42
Powered by FlippingBook